MYDA Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

MYDA Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-28,000	Closed	-$2.04M	–	129
2023 Q3	$2.04M	Buy	+28,000	New	+$2.24M	0.66%	41
2022 Q3	–	Sell	-41,000	Closed	-$3.04M	–	209
2022 Q2	$3.04M	Buy	+41,000	New	+$3.08M	0.85%	24
2022 Q1	–	Sell	-34,000	Closed	-$3.81M	–	265
2021 Q4	$3.81M	Buy	34,000 +22,000	+183%	+$2.65M	1.02%	28
2021 Q3	$1.51M	Buy	+12,000	New	+$1.55M	0.42%	62
2021 Q2	–	Sell	-10,000	Closed	-$1.36M	–	347
2021 Q1	$1.36M	Buy	+10,000	New	+$1.5M	0.38%	84
2020 Q1	–	Sell	-18,000	Closed	-$1.71M	–	173
2019 Q4	$1.71M	Buy	+18,000	New	+$1.56M	0.75%	39
2019 Q1	–	Sell	-10,000	Closed	-$718K	–	142
2018 Q4	$718K	Buy	+10,000	New	+$806K	1.23%	24
2018 Q1	–	Sell	-23,000	Closed	-$1.95M	–	184
2017 Q4	$1.95M	Buy	+23,000	New	+$1.93M	0.87%	27

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

MYDA Advisors's XBI Position: Q4 2023 in Review

MYDA Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 28,000 shares — an estimated $2.04M sold.

MYDA Advisors first reported a position in XBI in Q4 2017 and held it in 8 quarters. The position peaked at $3.81M in Q4 2021. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

MYDA Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
MYDA Advisors sold 28,000 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $2.04M.
MYDA Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 8 quarters.
MYDA Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.81M in Q4 2021.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on MYDA Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.